Regulatory bodies' official announcements (e.g., FDA, EMA)

Eli Lilly's Zepbound Weight Loss Drug Shows Promise in Treating Sleep Apnea

Jun 22, 2024, 10:54 PM

A new study has found that a popular weight loss drug may also help treat sleep apnea, a condition where individuals struggle to breathe while sleeping. The drug, which is commonly used for obesity, showed potential in reducing the severity of sleep apnea. This discovery was highlighted at the American Diabetes Association's 84th Annual Scientific Sessions. The study's findings suggest that the drug could offer a dual benefit for patients dealing with both obesity and sleep apnea. Additionally, the drug's ability to improve blood pressure and other health measures was noted, further enhancing its therapeutic profile. Eli Lilly's Zepbound helped resolve obstructive sleep apnea in 43-51.5% of patients.